AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19863455 — intervention group
Group type: COMPARATOR
Intervention: BZA 20 mg
Number of subjects: 652
Study 19863455 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 652
Study 17435957 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy milk (72 mg isoflavones/day)
Number of subjects: 79
Study 17435957 — intervention group
Group type: EXPERIMENTAL
Intervention: Cow's milk and isoflavone supplement (70 mg isoflavones/day)
Number of subjects: 79
Study 17435957 — intervention group
Group type: COMPARATOR
Intervention: Cow's milk and placebo supplement (control)
Number of subjects: 79
Study 15788292 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole 1 mg once daily
Number of subjects: 44
Study 15788292 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen 20 mg once daily
Number of subjects: 44
Study 11896339 — intervention group
Group type: EXPERIMENTAL
Intervention: IV fluid replacement (500 mL of HES)
Number of subjects: 60
Study 11896339 — intervention group
Group type: COMPARATOR
Intervention: No fluid replacement
Number of subjects: 60
Study 9442159 — intervention group
Group type: EXPERIMENTAL
Intervention: Sweeping of membranes
Number of subjects: 200
Study 9442159 — intervention group
Group type: COMPARATOR
Intervention: Control (vaginal examination for Bishop scoring only)
Number of subjects: 200
Study 8576296 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.5 mg intravenous glyburide (Gb)
Number of subjects: 8
Study 8576296 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.5 mg intravenous 4‐trans‐hydroxyglibenclamide (M1)
Number of subjects: 8
Study 8576296 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.5 mg intravenous 3‐cis‐hydroxyglibenclamide (M2)
Number of subjects: 8
Study 8576296 — intervention group
Group type: COMPARATOR
Intervention: 3.5 mg oral micronized glyburide (Gb)
Number of subjects: 8
Study 8576296 — intervention group
Group type: COMPARATOR
Intervention: Comparison of intravenous and oral administration of glyburide
Number of subjects: 8
Study 2198414 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapsone 100 mg daily, non-supervised for 3 years
Number of subjects: 195
Study 2198414 — intervention group
Group type: EXPERIMENTAL
Intervention: RMP 900 mg supervised, once weekly, 8 doses
Number of subjects: 195
Study 2198414 — intervention group
Group type: EXPERIMENTAL
Intervention: RMP 600 mg, once monthly, supervised, 6 doses with dapsone 100 mg daily unsupervised
Number of subjects: 195
Study 2198414 — intervention group
Group type: EXPERIMENTAL
Intervention: RMP 600 mg together with dapsone 100 mg daily, supervised for 6 days
Number of subjects: 195
Study 2198414 — intervention group
Group type: COMPARATOR
Intervention: Classical dapsone treatment
Number of subjects: 195
Study 30289444 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose ring (VCV, 91 mg; MK-2048, 10 mg)
Number of subjects: 19
Study 30289444 — intervention group
Group type: COMPARATOR
Intervention: Original-dose ring (VCV, 182 mg; MK-2048, 30 mg)
Number of subjects: 19
Study 30208766 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentaclethra macrophylla (akpaka) sauce
Number of subjects: 90
Study 30208766 — intervention group
Group type: EXPERIMENTAL
Intervention: Steamed bambara groundnut pudding (okpa)
Number of subjects: 90
Study 30208766 — intervention group
Group type: EXPERIMENTAL
Intervention: Maize + pigeon pea (ayaraya oka)
Number of subjects: 90
Study 30208766 — intervention group
Group type: EXPERIMENTAL
Intervention: Tomato stew
Number of subjects: 90
Study 30208766 — intervention group
Group type: EXPERIMENTAL
Intervention: Pterocarpus soyauxii (oha) soup
Number of subjects: 90
Study 30208766 — intervention group
Group type: EXPERIMENTAL
Intervention: Yam + pigeon pea (ayaraya ji)
Number of subjects: 90
Study 30208766 — intervention group
Group type: EXPERIMENTAL
Intervention: Various foods
Number of subjects: 90
Study 28275807 — intervention group
Group type: EXPERIMENTAL
Intervention: Semiconductor laser therapy combined with botulinum toxin A type injection (50 U injected into masseteric and temporal muscles, 5 injections at different sites on each side, treatment course of 2 weeks)
Number of subjects: 90
Study 28275807 — intervention group
Group type: COMPARATOR
Intervention: Semiconductor laser therapy (once per day for 1 week)
Number of subjects: 90
Study 24673738 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus casei 01 supplementation (10^8 CFU, one capsule daily for 8 weeks)
Number of subjects: 60
Study 24673738 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus casei 01 supplementation
Number of subjects: 60
Study 24673738 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 22301766 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg eicosapentaenoic acid (EPA) plus docosahexaenoic acid (DHA) and 2 g α-linolenic acid (ALA)
Number of subjects: 4153
Study 22301766 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA-DHA plus ALA
Number of subjects: 4153
Study 19159691 — intervention group
Group type: EXPERIMENTAL
Intervention: Verum acupuncture with high expectation
Number of subjects: 0
Study 19159691 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture with high expectation
Number of subjects: 0
Study 19159691 — intervention group
Group type: EXPERIMENTAL
Intervention: Verum acupuncture
Number of subjects: 0
Study 19159691 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 0
Study 17109475 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein
Number of subjects: 12
Study 17109475 — intervention group
Group type: COMPARATOR
Intervention: Casein
Number of subjects: 12
Study 17109475 — intervention group
Group type: COMPARATOR
Intervention: FREE AA
Number of subjects: 12
Study 15185464 — intervention group
Group type: EXPERIMENTAL
Intervention: Equivalence trials in cardiovascular medicine
Number of subjects: 0
Study 15185464 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-inferiority trials in cardiovascular medicine
Number of subjects: 0
Study 12206475 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol (50 microg twice daily)
Number of subjects: 33
Study 12206475 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 9703041 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioptic amorphic lenses training for 3 months
Number of subjects: 15
Study 7855683 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal manipulation
Number of subjects: 0
Study 7855683 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage
Number of subjects: 0
Study 7855683 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous muscle stimulation (TMS)
Number of subjects: 0
Study 7855683 — intervention group
Group type: EXPERIMENTAL
Intervention: Corset
Number of subjects: 0
Study 2571469 — intervention group
Group type: EXPERIMENTAL
Intervention: Bethanechol, 10 mg subcutaneously
Number of subjects: 132
Study 2571469 — intervention group
Group type: COMPARATOR
Intervention: Midazolam, 5 mg intramuscularly
Number of subjects: 132
Study 2571469 — intervention group
Group type: COMPARATOR
Intervention: Bethanechol and midazolam in combination
Number of subjects: 132
Study 2571469 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study 2571469 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 132
Study 773581 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine (DPH) 25 mg every 4 hr for four doses
Number of subjects: 0
Study 773581 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine (DPH) 50 mg every 4 hr for four doses
Number of subjects: 0
Study 773581 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30859862 — intervention group
Group type: EXPERIMENTAL
Intervention: HMB-FA (3 g/day; n=14)
Number of subjects: 44
Study 30859862 — intervention group
Group type: EXPERIMENTAL
Intervention: HMB-Ca (3 g/day; n=15)
Number of subjects: 44
Study 30859862 — intervention group
Group type: COMPARATOR
Intervention: Placebo (cornstarch, 3 g/day; n=15)
Number of subjects: 44
Study 28727581 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 900 mg
Number of subjects: 697
Study 28727581 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 697
Study 25542677 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotionally charged auditory stimulation (happy sounds)
Number of subjects: 104
Study 25542677 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotionally charged auditory stimulation (sad sounds)
Number of subjects: 104
Study 25542677 — intervention group
Group type: COMPARATOR
Intervention: No auditory stimulation (control)
Number of subjects: 104
Study 25542677 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotionally charged auditory stimulation (happy or sad sounds)
Number of subjects: 104
Study 23417633 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-facilitated cognitive group (NFCG) intervention
Number of subjects: 30
Study 23417633 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 30
Study 21332331 — intervention group
Group type: EXPERIMENTAL
Intervention: Silymarin 140 mg 3 times daily
Number of subjects: 80
Study 21332331 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E 400 IU/day
Number of subjects: 80
Study 21332331 — intervention group
Group type: EXPERIMENTAL
Intervention: Silymarin 140 mg 3 times daily and Vitamin E 400 IU/day
Number of subjects: 80
Study 21332331 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study 17868415 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional laparoscopic needle-holder (Karl Storz, Tuttlingen, Germany)
Number of subjects: 20
Study 17868415 — intervention group
Group type: COMPARATOR
Intervention: First-generation articulating laparoscopic needle-holder (Cambridge Endo, Framingham, MA, USA)
Number of subjects: 20
Study 16047465 — intervention group
Group type: EXPERIMENTAL
Intervention: Colesevelam HCl 2.3 g/day
Number of subjects: 24
Study 16047465 — intervention group
Group type: EXPERIMENTAL
Intervention: Colesevelam HCl 3.8 g/day
Number of subjects: 24
Study 16047465 — intervention group
Group type: EXPERIMENTAL
Intervention: Colesevelam HCl 2.3 g/day and 3.8 g/day
Number of subjects: 24
Study 12019592 — intervention group
Group type: EXPERIMENTAL
Intervention: Worksite exercise training guided by a physiotherapist (60-minute sessions once a week for 8 months)
Number of subjects: 260
Study 12019592 — intervention group
Group type: COMPARATOR
Intervention: Control group (received a 30-minute feedback on physical capacity and individual exercise prescription and counseling)
Number of subjects: 260
Study 10084421 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventable ADRs
Number of subjects: 370
Study 10084421 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictable ADRs
Number of subjects: 370
Study 10084421 — intervention group
Group type: EXPERIMENTAL
Intervention: Severity of ADRs
Number of subjects: 370
Study 10084421 — intervention group
Group type: EXPERIMENTAL
Intervention: Length of hospitalization
Number of subjects: 370
Study 10084421 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence of preventable ADRs
Number of subjects: 370
Study 10084421 — intervention group
Group type: EXPERIMENTAL
Intervention: Most predictable ADRs
Number of subjects: 370
Study 10155357 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol, 200 micrograms with HFA134a
Number of subjects: 0
Study 10155357 — intervention group
Group type: COMPARATOR
Intervention: CFC preparations
Number of subjects: 0
Study 10155357 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol and CFC preparations
Number of subjects: 0
Study 2257871 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 8
Study 2257871 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 8
Study 549537 — intervention group
Group type: EXPERIMENTAL
Intervention: d‐propranolol
Number of subjects: 6
Study 549537 — intervention group
Group type: EXPERIMENTAL
Intervention: dl‐propranolol
Number of subjects: 6
Study 549537 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 28890081 — intervention group
Group type: EXPERIMENTAL
Intervention: Valvular surgery alone
Number of subjects: 1462
Study 28890081 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant valvular and coronary artery bypass grafting surgery
Number of subjects: 1462
Study 28890081 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of cardiopulmonary bypass
Number of subjects: 1462
Study 28890081 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventricular pacing
Number of subjects: 1462
Study 28890081 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant coronary artery bypass grafting and valvular surgery
Number of subjects: 1462
Study 28890081 — intervention group
Group type: EXPERIMENTAL
Intervention: Occurrence of postoperative atrial fibrillation
Number of subjects: 1462
Study 27049643 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (600 IU/day)
Number of subjects: 58
Study 27049643 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (2000 IU/day)
Number of subjects: 58
Study 27049643 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (4000 IU/day)
Number of subjects: 58
Study 27049643 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 25217122 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-cross-linked hyaluronic acid (HA) hydrogel
Number of subjects: 30
Study 25217122 — intervention group
Group type: COMPARATOR
Intervention: Carboxymethylcellulose (CMC) viscous foam
Number of subjects: 30
Study 24364108 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercising larynx and genioglossus
Number of subjects: 54
Study 24364108 — intervention group
Group type: COMPARATOR
Intervention: UPPP surgery (Control group 1)
Number of subjects: 54
Study 24364108 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control group 2)
Number of subjects: 54
Study 19812500 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone-conducted vibration (BCV)
Number of subjects: 27
Study 19812500 — intervention group
Group type: COMPARATOR
Intervention: Air-conducted sound (ACS)
Number of subjects: 27
Study 18546441 — intervention group
Group type: EXPERIMENTAL
Intervention: S-ketamine
Number of subjects: 12
Study 18546441 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 16150370 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback assisted diaphragmatic breathing and systematic relaxation
Number of subjects: 192
Study 16150370 — intervention group
Group type: COMPARATOR
Intervention: Propranolol 80 mg/day
Number of subjects: 192
Study 12622760 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.0 g/day mesalazine
Number of subjects: 206
Study 12622760 — intervention group
Group type: COMPARATOR
Intervention: 2.4 g/day mesalazine
Number of subjects: 206
Study 10676721 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol (0.25 microg/d) plus calcium carbonate (500 mg/d of elemental calcium)
Number of subjects: 30
Study 10676721 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 9345358 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy + Wertheim‐Meigs + radiotherapy
Number of subjects: 205
Study 9345358 — intervention group
Group type: COMPARATOR
Intervention: Control (Wertheim‐Meigs + adjuvant radiotherapy)
Number of subjects: 205
Study 9345358 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Number of subjects: 205
Study 9345358 — intervention group
Group type: COMPARATOR
Intervention: Control (unresectable bulky tumors)
Number of subjects: 205
Study 8379564 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovering alcoholics
Number of subjects: 220
Study 8379564 — intervention group
Group type: COMPARATOR
Intervention: Nonalcoholics
Number of subjects: 220
Study 8379564 — intervention group
Group type: EXPERIMENTAL
Intervention: Comorbidity of alcoholism and major depression
Number of subjects: 220
Study 8379564 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation
Number of subjects: 220
Study 2876700 — intervention group
Group type: EXPERIMENTAL
Intervention: Benztropine mesylate 2 mg b.i.d. (withdrawal)
Number of subjects: 39
Study 2876700 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 29731164 — intervention group
Group type: EXPERIMENTAL
Intervention: Wellness Education (WE)
Number of subjects: 126
Study 29731164 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 126
Study 27512927 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin 1200 mg daily for 6 months
Number of subjects: 262
Study 27512927 — intervention group
Group type: COMPARATOR
Intervention: Norfloxacin 400 mg daily for 6 months
Number of subjects: 262
Study 25203576 — intervention group
Group type: EXPERIMENTAL
Intervention: High-pitch ultra-low-dose CT
Number of subjects: 60
Study 22642357 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonic contraction of lower half of the face
Number of subjects: 0
Study 22642357 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonic contraction of upper half of the face
Number of subjects: 0
Study 22642357 — intervention group
Group type: EXPERIMENTAL
Intervention: Both upper and lower half manipulations
Number of subjects: 0
Study 22642357 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral lower half-face combined with emotional expression
Number of subjects: 0
Study 22642357 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral upper half-face combined with emotional expression
Number of subjects: 0
Study 22642357 — intervention group
Group type: EXPERIMENTAL
Intervention: Both upper and lower half manipulations with neutral faces
Number of subjects: 0
Study 22642357 — intervention group
Group type: EXPERIMENTAL
Intervention: Both manipulations
Number of subjects: 0
Study 20549168 — intervention group
Group type: EXPERIMENTAL
Intervention: Ottobock B500
Number of subjects: 12
Study 19020244 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower injection rate protocol: 20 mL of gadopentetate dimeglumine at 2 mL/s, 8 mL of gadopentetate dimeglumine at 1 mL/s, and 20 mL of saline solution at 1 mL/s.
Number of subjects: 80
Study 19020244 — intervention group
Group type: COMPARATOR
Intervention: Higher injection rate protocol: 20 mL of gadopentetate dimeglumine at 1.2 mL/s, 8 mL of gadopentetate dimeglumine at 0.7 mL/s, and 20 mL of saline solution at 0.7 mL/s.
Number of subjects: 80
Study 16392777 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-day treatment with trimethoprim
Number of subjects: 100
Study 16392777 — intervention group
Group type: COMPARATOR
Intervention: Five-day treatment with trimethoprim
Number of subjects: 100
Study 12190747 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler guided fluid optimisation (Group D)
Number of subjects: 57
Study 12190747 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group C)
Number of subjects: 57
Study 10648340 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined-frequency jet ventilation (10 min, 15 and 600 breaths/min, inspiration/expiration time ratio = 1, driving pressure 750-1500 mm Hg)
Number of subjects: 23
Study 10648340 — intervention group
Group type: COMPARATOR
Intervention: Monofrequent jet ventilation (low-frequency group: 15 breaths/min; high-frequency group: 600 breaths/min, 20 min)
Number of subjects: 23
Study 8676600 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 micrograms iodine per day (group A)
Number of subjects: 106
Study 8676600 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 micrograms iodine plus 100 micrograms levothyroxine per day (group B)
Number of subjects: 106
Study 1534424 — intervention group
Group type: EXPERIMENTAL
Intervention: Dacron
Number of subjects: 165
Study 1534424 — intervention group
Group type: COMPARATOR
Intervention: ePTFE
Number of subjects: 165
Study 3931596 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol added to potassium crystalloid solution
Number of subjects: 58
Study 3931596 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% Albumin added to potassium crystalloid solution
Number of subjects: 58
Study 3931596 — intervention group
Group type: COMPARATOR
Intervention: Standard potassium crystalloid solution
Number of subjects: 58
Study 31103533 — intervention group
Group type: EXPERIMENTAL
Intervention: IMPACT (problem-solving + education intervention)
Number of subjects: 607
Study 31103533 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 607
Study 29635610 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person mindfulness training (IP)
Number of subjects: 0
Study 29635610 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual world mindfulness training (VW)
Number of subjects: 0
Study 29635610 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness Training (combined IP and VW)
Number of subjects: 0
Study 29635610 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 0
Study 27314118 — intervention group
Group type: COMPARATOR
Intervention: External connection (EC) implants
Number of subjects: 120
Study 27314118 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal connection (IC) implants
Number of subjects: 120
Study 27314118 — intervention group
Group type: EXPERIMENTAL
Intervention: Both EC and IC implants
Number of subjects: 120
Study 23399677 — intervention group
Group type: COMPARATOR
Intervention: NerBloc® (rimabotulinumtoxinB) 2,500 U
Number of subjects: 0
Study 23399677 — intervention group
Group type: COMPARATOR
Intervention: NerBloc® (rimabotulinumtoxinB) 5,000 U
Number of subjects: 0
Study 23399677 — intervention group
Group type: COMPARATOR
Intervention: NerBloc® (rimabotulinumtoxinB) 10,000 U
Number of subjects: 0
Study 23399677 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22254516 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic stimulation
Number of subjects: 64
Study 22254516 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 64
Study 19246708 — intervention group
Group type: EXPERIMENTAL
Intervention: Prism Adaptation (PA)
Number of subjects: 20
Study 19246708 — intervention group
Group type: COMPARATOR
Intervention: Neutral Pointing (NP)
Number of subjects: 20
Study 19246708 — intervention group
Group type: EXPERIMENTAL
Intervention: Prism Adaptation (PA) after NP treatment
Number of subjects: 20
Study 17101300 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin (1g after breakfast and 1g after evening meal) plus sulfasalazine or mesalamine
Number of subjects: 89
Study 17101300 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus sulfasalazine or mesalamine
Number of subjects: 89